Effect of Metformin on a Preeclampsia-Like Mouse Model Induced by High-Fat Diet

Abstract EN

Background.

Metformin has been reported to decrease insulin resistance and is associated with a lower risk of pregnancy-induced hypertension and preeclampsia.

It is widely accepted that the placenta plays a crucial role in the development of preeclampsia.

Our aim is to explore the effect of metformin on preeclampsia.

Study Design.

We examined control diet-fed (isocaloric diet) pregnant mice (CTRL group), pregnant mice fed a high-fat diet (HF group), and high-fat-diet-fed pregnant mice treated with metformin (HF-M group).

The HF mice were fed a high-fat diet six weeks before pregnancy to establish a preeclampsia-like model; then, the group was randomly divided into a HF group and a HF-M group after pregnancy.

Blood pressure, urine protein, pregnancy outcomes, protein expression, and histopathological changes in the placentas of all groups were examined and statistically analysed.

Results.

We observed that metformin significantly improved high blood pressure, proteinuria, and foetal and placental weights in the HF-M group compared with the HF group.

Metformin significantly improved placental labyrinth and foetal vascular development in preeclampsia.

In addition, metformin effectively increased matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) levels in the placenta.

Conclusions.

Our results suggest that metformin can improve preeclamptic symptoms and pregnancy outcomes.